The short version of eumelanin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-22 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
== Characteristics == Kava was historically grown only in the Pacific islands of Hawaii, Federated States of Micronesia, Vanuatu, Fiji, the Samoas, and Tonga. It appears to have originated in Vanuatu; an inventory of P. methysticum distribution showed it was cultivated on numerous islands of Micronesia, Melanesia, Polynesia, and Hawaii, whereas specimens of P. wichmannii were all from Papua New Guinea, the Solomon Islands, and Vanuatu. Traditionally, plants are harvested around four years of age, as older plants have higher concentrations of kavalactones. After reaching about 2 metres (6.6 ft) in height, plants grow a wider stalk and additional stalks, but not much taller. The roots can reach a depth of 60 centimetres (2.0 ft).
=== Administration === The MMR vaccine is administered by a subcutaneous injection, the first dose typically at twelve months of age. The second dose may be given as early as one month after the first dose. The second dose is a dose to produce immunity in the small number of persons (2–5%) who fail to develop measles immunity after the first dose. In the US it is done before entry to kindergarten because that is a convenient time. Areas where measles is common typically recommend the first dose at nine months of age and the second dose at fifteen months of age.
=== In tRNA === Wobble pairing rules. Watson–Crick base pairs are shown in bold. Parentheses denote bindings that work but will be favoured less. A leading x denotes derivatives (in general) of the base that follows.
Sources: en.wikipedia.org
=== Sequence and structure === Calciseptine itself consists of 60 amino acids and has been fully sequenced: RICYIHKASL PRATKTCVEN TCYKMFIRTQ REYISERGCG CPTAMWPYQT ECCKGDRCNK The three-dimensional structure of calciseptine has not been determined experimentally. However, another toxin found in black mamba venom, called FS2, sequentially differs from calciseptine in only three residues: it contains a serine instead of isoleucine in position 5, a histidine instead of glutamine in position 30, and a glutamine instead of glutamic acid in position 32. A three-dimensional structure of FS2 has been determined using NMR, and because of the minor sequential differences, this can serve as a model of the calciseptine structure.
=== 11 April === Russia launched a massive air attack on cities and energy infrastructure across Ukraine, killing five people in Mykolaiv and destroying the Trypilska thermal power plant in Ukrainka, Kyiv Oblast. Two storage facilities belonging to the state gas firm Naftogaz were also targeted. President Zelenskyy said that the power plant was destroyed after air defenses ran out of missiles after intercepting seven Russian missiles, resulting in four other missiles hitting the facility. The FSB claimed to have thwarted an attempted landing by Ukrainian special forces in occupied Kherson Oblast, inflicting casualties and capturing a commando. Ukrainian authorities ordered the evacuation of families with children from 47 communities in Kharkiv Oblast near the border with Russia due to Russian attacks. Ukrainian military commanders convinced the Verkhovna Rada to drop a clause from a bill on mobilization of Ukrainian military personnel that allowed soldiers who had fought for 36 months a chance to be discharged. Citing the ongoing Russian offensive, the officers claimed that the clause would "weaken the defence forces". The bill was passed later in the day after over four thousand amendments were submitted since its introduction in February 2024. It must now be signed into law by Zelenskyy.
== Departments == In hospitals and other patient-care settings, laboratory medicine is provided by the Department of Pathology and Medical Laboratory, and generally divided into two sections, each of which will be subdivided into multiple specialty areas. The two sections are:
Sources: en.wikipedia.org
The indictment against Duterte, which was made public on September 22, 2025, accused him of involvement in the murders of 76 people between 2013 and 2018. Fifty-seven of the killings took place during his presidency, and the other 19 occurred during his third term as mayor of Davao City. On October 10, 2025, the ICC rejected a request from Duterte to be released from detention, arguing that he posed a risk of fleeing and would not be willing to return for trial, as well as presenting concerns about potential witness intimidation if he were granted freedom. On January 26, 2026, the ICC declared Duterte fit for trial, overruling efforts by his lawyers to have the charges dismissed on health grounds. Duterte waived his right to appear at any proceedings, with his lawyer Nicholas Kaufman stating that he was not mentally fit to follow the hearing. On April 23, 2026, the Pre-Trial Chamber of the ICC committed Duterte to trial. In May 2026, the ICC Pre-Trial Chamber I denied Duterte's appeal to dismiss the charges. That same month the Trial Chamber III of the ICC set the opening statements in Duterte's trial to begin on November 30, 2026. On September 3, 2026, his defense asked the ICC to verify digital evidence presented by the prosecution, saying that much of the material against Duterte had been taken from open-source and user-generated content from the internet.
Proposed mitigation strategies include factoring potential environmental costs prior to model development or data collection, increasing efficiency of data centers to reduce electricity/energy usage, building more efficient machine learning models, minimizing the number of times that models need to be retrained, developing a government-directed framework for auditing the environmental impact of these models, regulating for transparency of these models, regulating their energy and water usage, encouraging researchers to publish data on their models' carbon footprint, and increasing the number of subject matter experts who understand both machine learning and climate science.
== Efficacy and side effects == Cholinergic nerves play an important role in the normal function of the central nervous, endocrine, neuromuscular, immunological, and respiratory system. As all cholinergic fibers contain high concentrations of ACh and AChE at their terminals, inhibition of AChE can impair their function. So exposure to azinphosmethyl, whereas it inhibits AChEs, may disturb a lot of important systems and may have various effects. In the autonomic nervous system, accumulation of acetylcholine leads to the overstimulation of muscarinic receptors of the parasympathetic nervous system. This can affect exocrine glands (increased salivation, perspiration, lacrimation), the respiratory system (excessive bronchial secretions, tightness of the chest, and wheezing), the gastrointestinal tract (nausea, vomiting, diarrhea), the eyes (miosis, blurred vision) and the cardiovascular system (decrease in blood pressure, and bradycardia). Overstimulation of the nicotinic receptors in the para- or sympathetic nervous system may also cause adverse effects on the cardiovascular system, such as pallor, tachycardia and increased blood pressure. In the somatic nervous system, accumulation of acetylcholine may cause muscle fasciculation, paralysis, cramps, and flaccid or rigid tone. Overstimulation of the nerves in the central nervous system, specifically in the brain, may result in drowsiness, mental confusion and lethargy. More severe effects on the central nervous system include a state of coma without reflexes, cyanosis and depression of the respiratory centers.
In March 2001 the license for Trovan was withdrawn in Europe, by the European Commission due to liver toxicity and some deaths. In June 2010, the US Supreme Court rejected Pfizer's appeal against a ruling allowing lawsuits by the Nigerian families to proceed. In December 2010, the United States diplomatic cables leak indicated that Pfizer hired investigators to find evidence of corruption against Nigerian attorney general Michael Aondoakaa to persuade him to drop legal action. The Washington Post reporter Joe Stephens, who helped break the story in 2000, called these actions "dangerously close to blackmail". In response, the company released a press statement describing the allegations as "preposterous" and saying that it acted in good faith. Aondoakka, who had allegedly demanded bribes from Pfizer in return for a settlement of the case, was declared unfit for office and had his U.S. visa revoked in association with corruption charges in 2010. The lawsuits were eventually settled out of court. Pfizer committed to paying US$35 million "to compensate the families of children in the study", another $30 million to "support healthcare initiatives in Kano", and $10 million to cover legal costs. Payouts began in 2011.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.